Analysis: Venture capital firm could benefit from swine flu outbreak

04/27/2009 | Reuters

Kleiner Perkins Caufield & Byers is expected to benefit from the swine flu outbreak because of its investments in pandemic and biodefense companies, including BioCryst Pharmaceuticals and Novavax, according to Thomson Reuters Private Equity Week. While BioCryst said its vaccine is still in clinical trials, Novavax's CEO expressed confidence the company can create a vaccine for the virus in 12 weeks.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT